Delving into the Latest Updates on Naftopidil with Synapse

This study analyzed the adverse events associated with 5-ALA in PDD and assessed the preoperative use of a1-blockers as a risk factor for hypotension.A total of 203 patients (161 male and 42 female) were enrolled in this study.Five-ALA were received 20 mg/kg. Patient age ranged from 45 to 96 years, with a mean age of 73.3 years.RASI were regularly used to 72 patients (31.0%), and Ca-blockers to 69 patients (34.0%).Antihypertensive medication was taken on the day of surgery among 58 patients (28.6%) as followed by the discretion of the anesthesiologists.a1-blockers were regularly used to 25 patients (12.3%).The details of a1-blockers were as follows: 16 for tamsulosin, 2 for naftopidil, and 7 for silodosin.The duration of medication ranged from 2 mo to 16 years, with a median of 2 years.Spinal anesthesia was performed on 159 patients (78.3%).Hypotension was intraoperatively observed in 63 patients (30.9%), nausea in 62 patients (30.4%), and decreased percutaneous oxygen saturation of <90% in 10 patients (12.3%).Postoperative hypotension was revealed among three of the enrolled patients, whereas preoperative hypotension was not.Table 1 summarizes the results of risk factor anal. for a decrease in SBP during PDD-assisted TURBT.Both analyses revealed general anesthesia, regular use of angiotensin receptor blocker (ARB) combination medicine, Ca-blockers, and preoperative a1-blockers as significant risk factors for hypotension in PDD-assisted TURBT.

01 Jan 2025·HUMAN IMMUNOLOGY

Identification of immune characteristics between different subtypes in kidney renal clear cell carcinoma based on lysosome-related genes to assist immunotherapy

Article

Author: Wang, Fei ; Jin, Yigang ; Zhang, Qihui ; Wu, Yuntao ; Guo, Xiao

Previous studies have revealed the essential role of lysosomes in human diseases, including cancer. However, there is a lack of in-depth systematic research on its function in kidney renal clear cell carcinoma (KIRC). In this project, we collected the public dataset of KIRC and selected lysosomal genes tightly linked with survival. Cluster analysis uncovered that these genes possess good classification ability and can divide KIRC patients into multiple subtypes with different survival rates. Enrichment analyses revealed that the main biological processes associated with differentially expressed genes (DEGs) in the two representative subpopulations with the largest survival differences (cluster1 and cluster2) were steroid metabolic process, neutrophil extracellular trap formation, and tyrosine metabolism. The immune-related analysis demonstrated notable differences in immune cell infiltration levels between cluster1 and cluster2 subpopulations of KIRC. More specifically, Tfh and TIL were highly infiltrated in the cluster1, and Type II IFN response, mast cells, and basophils were highly infiltrated in the cluster2. The immunotherapy-related analysis demonstrated that cluster1 may be more sensitive to immunotherapy and more likely to benefit from immunotherapy due to its higher immune checkpoint expression, ESTIMATE score, immune score, and higher immunophenoscore (IPS). In addition, gene mutations occurred in the two subtypes, exhibiting similar mutation patterns between the two subtypes. Finally, based on the cMAP database, we identified some small molecules that may target DEGs between the two subtypes, such as epibatidine, mepyramine, and reboxetine. In conclusion, our investigation unearthed that different subtypes of KIRC patients exhibited different survival outcomes and sensitivity to the immune microenvironment, as well as different responses to immunotherapy. These findings may be beneficial for further mechanistic exploration and therapeutic research of KIRC in the future.

01 Jan 2025·CRYSTAL GROWTH & DESIGN

Organic Crystals: Comprehensive Understanding of Proton States of Naftopidil Salts via XPS

Author: Addala, Uma Mahesh ; Dandela, Rambabu ; Tothadi, Srinu

In this study, 18 Naftopidil (NFPD) binary salts were synthesized and then analyzed via XPS.Among these salts, nine known binary salts were initially investigated via SCXRD, where in every binary complex, the carboxylic acid (-COOH) proton is transferred to N of naftopidil.Afterward, these nine naftopidil salts were examined via XPS, where N 1s binding energies of salts showed a significant binding energy shift (2.1 to 2.6 eV) compared to neutral N 1s binding energies of naftopidil.Later, nine novel complexes were synthesized and explored via XPS.Interestingly, these new crystalline materials also manifest considerable N 1s binding energy shifts (1.9 to 2.4 eV) compared to the neutral N 1s binding energies of naftopidil.After a detailed evaluation of XPS exptl. results, new complexes were predicted as naftopidil salts, and SCXRD studies further confirmed these results.Moreover, all these crystalline materials were also characterized by Powder X-ray diffraction (PXRD) and Fourier Transform IR Spectroscopy (FT-IR).Intermol. interactions are further studied by Hirshfeld Surface Anal. (HSA).

1

News (Medical) associated with Naftopidil

10 Aug 2023

·www.pharmaindustrial-india.com

Sigachi Industries Limited Forays Into API Business With Strategic Majority Stake In Trimax Bio Sciences

Sigachi Industries Limited, a renowned name in the excipient segment of pharmaceutical industry, is excited to announce its strategic expansion into the API (Active Pharmaceutical Ingredient) business with the successful acquisition of majority stake (80%) of a state-of-the-art API manufacturing company, Trimax Bio Sciences, located in Raichur, Karnataka. The acquisition marks a significant milestone in Sigachi's journey as it reinforces it’s commitment to providing cutting-edge solutions to the global pharmaceutical market. With this strategic move, Sigachi is poised to solidify its position as a leading player in the healthcare industry, catering to the growing demand for high-quality APIs. The API unit, located in Raichur, Karnataka, 180kms from Hyderabad, is equipped with cutting-edge technology and is in compliance with the stringent international quality standards of USFDA, EMEA and WHO. Additionally, the API unit is approved by USFDA for advanced & critical intermediates. With a well-established track record of excellence in research, development, and manufacturing, the acquired API unit will synergize seamlessly with Sigachi's existing portfolio of excipients and will provide one stop solution for customer’s API & non-API needs. Commenting on this strategic development, Mr. Amit Raj Sinha the MD & CEO of Sigachi Industries Limited, stated, "We are thrilled to venture into the API business, which presents vast opportunities to further strengthen our presence in the pharmaceutical industry. The acquisition of this well-equipped API unit aligns perfectly with our mission to deliver superior healthcare solutions globally. This expansion is a testament to our commitment to innovation and customer satisfaction." The API market plays a crucial role in the pharmaceutical industry, providing the essential building blocks for various medications. With this acquisition, Sigachi is set to enhance its capabilities in developing and supplying a diverse range of APIs, catering to a wide spectrum of therapeutic areas, including cardiovascular, anti-diabetic, anti-infective, anti-viral, and central nervous system medications, among others with molecules like Pregabalin, Ritonavir, Metformin Hcl, Propafenone Hcl, Atorvastatin Ca Trihydrate, Nimorazole, Naftopidil, Meclizine Hcl & their intermediates. Sigachi Industries Limited envisions becoming a key player in the API market by leveraging its strong R&D capabilities, cutting-edge manufacturing infrastructure, and unwavering focus on quality. With a strong expertise in excipient manufacturing for Oral Dosage Formulation built over last three decades, Sigachi's foray into API business opens up new doors for further collaboration with it’s customer operating in over 60 countries.

Drug ApprovalAcquisition

100 Deals associated with Naftopidil

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01674	Naftopidil	G04CA	DB12092

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Dysuria	Japan	-	25 Dec 1998
Prostatic Hyperplasia	Japan	-	25 Dec 1998

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Medical device discomfort	Phase 3	United States	Dong-A ST Co., Ltd.	01 May 2014
Ureterolithiasis	Phase 3	United States	Dong-A ST Co., Ltd.	01 May 2014
Pain, Postoperative	Phase 3	South Korea	Dong-A ST Co., Ltd.	25 Oct 2013
Urinary Bladder, Neurogenic	Phase 2	Japan	Asahi Kasei Corp.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AUA2011	Not Applicable	Calculus, Ureteral	99	Naftopidil 75mg	izduofocdg(xfnqiubwmx) = nnolkhpanh jbkjwpzdba (fgzwyhrygt )	Positive	01 Apr 2011
				Flopropione 240mg	izduofocdg(xfnqiubwmx) = jbselixebd jbkjwpzdba (fgzwyhrygt )
1297 (AUA2011)	Not Applicable	Prostatic Cancer	212	Naftopidil	lleyfisooj(qikbupaqnb) = eumiwonffu bhwfhurnav (hxxmbgkoxh )	Positive	01 Apr 2011
				Tamsulosin	lleyfisooj(qikbupaqnb) = cjphrixmhu bhwfhurnav (hxxmbgkoxh )